Literature DB >> 12639653

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.

Kevin J Gancarczyk1, Hongyu Wu, David G McLeod, Christopher Kane, Leo Kusuda, Raymond Lance, Judy Herring, John Foley, Dalton Baldwin, Jay T Bishoff, Douglas Soderdahl, Judd W Moul.   

Abstract

OBJECTIVES: To develop probability nomograms to predict pathologic outcome at the time of radical prostatectomy (RP) on the basis of established prognostic factors and prostate biopsy quantitative histology.
METHODS: Using information from the database of the Center for Prostate Disease Research (CPDR), univariate and multivariate analyses were performed on 1510 men who had undergone transrectal ultrasound and biopsy for diagnosis and had radical prostatectomy as primary therapy, with variables of age, race, clinical stage, pretreatment prostate-specific antigen (PSA), biopsy Gleason sum, and percentage of biopsy cores positive for cancer (total number of cores positive for cancer divided by the total number of cores obtained). The percentages of biopsy cores positive were grouped as less than 30%, 30% to 59%, and greater than or equal to 60%. The three most significant variables were used to develop probability nomograms for pathologic stage.
RESULTS: PSA, biopsy Gleason sum, and percentage of cores positive were the three most significant independent predictors of pathologic stage. The assigned percentage of biopsy core-positive subgroups along with pretreatment PSA and highest Gleason sum were used to develop probability nomograms for pathologic stage.
CONCLUSIONS: Pretreatment PSA, highest biopsy Gleason sum, and the percentage of cores positive for cancer are the most significant predictors for pathologic stage after radical prostatectomy. On the basis of these findings, CPDR probability nomograms were developed to predict pathologic outcome at the time of RP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639653     DOI: 10.1016/s0090-4295(02)02287-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 2.  The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.

Authors:  Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman
Journal:  BJU Int       Date:  2010-03-15       Impact factor: 5.588

3.  Significance of the percentage of prostate needle biopsy cores with cancer as a predictor of disease extension in radical prostatectomy specimens in Japanese men.

Authors:  Iori Sakai; Ken-ichi Harada; Isao Hara; Hiroshi Eto; Hideaki Miyake
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network.

Authors:  Sang Youn Kim; Sung Kyoung Moon; Dae Chul Jung; Sung Il Hwang; Chang Kyu Sung; Jeong Yeon Cho; Seung Hyup Kim; Jiwon Lee; Hak Jong Lee
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

5.  Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer.

Authors:  Brian Kim; Rodney H Breau; Demetri Papadatos; Dean Fergusson; Steve Doucette; Ilias Cagiannos; Chris Morash
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

6.  High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy.

Authors:  Alcides Chaux; Daniel A Fajardo; Nilda Gonzalez-Roibon; Alan W Partin; Mario Eisenberger; Theodore L DeWeese; George J Netto
Journal:  Urology       Date:  2011-12-14       Impact factor: 2.649

7.  Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.

Authors:  Takuya Koie; Koji Mitsuzuka; Takahiro Yoneyama; Shintaro Narita; Sadafumi Kawamura; Yasuhiro Kaiho; Norihiko Tsuchiya; Tatsuo Tochigi; Tomonori Habuchi; Yoichi Arai; Chikara Ohyama; Tohru Yoneyama; Yuki Tobisawa
Journal:  Int J Clin Oncol       Date:  2014-04-29       Impact factor: 3.402

8.  Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death.

Authors:  M Tarján
Journal:  Indian J Urol       Date:  2010 Jan-Mar

9.  PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Authors:  Sungmin Woo; Sang Youn Kim; Joongyub Lee; Seung Hyup Kim; Jeong Yeon Cho
Journal:  Eur Radiol       Date:  2016-02-04       Impact factor: 5.315

10.  Saturation biopsy protocol enhances prediction of pT3 and surgical margin status on prostatectomy specimen.

Authors:  Aurélien Descazeaud; Mark Rubin; Stéphanie Chemama; Stéphane Larré; Laurent Salomon; Yves Allory; Dimitri Vordos; Andras Hoznek; René Yiou; Dominique Chopin; Claude Abbou; Alexandre de la Taille
Journal:  World J Urol       Date:  2006-11-07       Impact factor: 3.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.